BCR-ABL1 p210 Major Molecular Response (MMR) [Presence] in Blood or Tissue by Molecular genetics method --post treatment

t(ABL1,BCR)p210/cntrl.0.1% p Tx Bld/T Ql

Definition

Patient's with CML and undergoing tyrosine kinase inhibitor (TKI) therapy may be monitored to assess their treatment response (reduction in BCR-ABL1 transcripts) to therapy. A major molecular response (MMR) occurs when the ratio of BCR-ABL1 transcripts to control gene is less than or equal to 0.1% according to the International Scale (IS), a consensus standardized measurement scale intended to allow direct comparison of BCR-ABL1 major breakpoint (b2a2, b3a2) RNA levels in any laboratory adopting its use. Studies have demonstrated that achieving MMR within 18 months following TKI therapy is associated with a minimal risk of progression at 84 months (NCCN Guidelines CML, 2013).

t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1%^post treatment

ABL; After; ALL; bcr/abl; BCR1; bcr-abl1; Blood; Breakpoint cluster region; Chronic myeloid leukemia; CML; D22S11; D22S662; DNA; e13a2; e14a2; gene fusion; gene translocation; Genetics; Hematology; Heme; Heredity; Heritable; Inherited; JTK7; major breakpoints; Mbr; Mcr; minor breakpoints; Molecular genetics; Molecular pathology; MOLPATH; Ordinal; p Tx; p150; p210; PCR; Ph chromosome; Philadelphia chromosome; PHL; Point in time; PR; PST; QL; Qual; Qualitative; Random; RNA; Screen; T prime; t(9,22)(ABL1,BCR) gene translocation; t(9,22)(ABL1,BCR) p210 gene translocation; t(9,22)(ABL1,BCR) Translocation; t(9,22)(q34,q11); t(9,22)(q34.1,q11); t(9;22)(ABL1,BCR); t(ABL1,BCR)b2a2; t(ABL1,BCR)p210; Tissue; Tissue, unspecified; translocation; Tx; v-abl Abelson murine leukemia viral oncogene homolog 1; WB; Whole blood; Whole blood or Tissue

27 further terms